Benzinga | Aug 6, 2020 08:23AM EDT

Adaptimmune Therapeutics Q2 EPS $(0.04) Beats $(0.23) Estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.23) by 82.61 percent. This is a 42.86 percent increase over losses of $(0.07) per share from the same period last year.